Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast has disclosed a change in director Lyn Cobley’s shareholding, with the board member purchasing 30,000 ordinary shares on-market at A$3.20 per share, a total consideration of A$96,000. Following the transaction, Cobley holds 30,000 shares directly and maintains an existing indirect holding of 33,000 shares, signalling increased personal financial commitment to the company and potentially reinforcing market confidence in Mesoblast’s outlook among investors and other stakeholders.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company focused on developing and commercialising cell-based regenerative medicines. The company targets serious and chronic conditions, leveraging its proprietary mesenchymal lineage cell technologies to address significant unmet medical needs in global markets.
YTD Price Performance: 12.87%
Average Trading Volume: 4,144,307
Technical Sentiment Signal: Buy
Current Market Cap: A$3.94B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.